Blood sugar and weight
What human research has studied for glucose control, diabetes risk and body weight, across every ingredient in this guide, strongest evidence first. A grade describes the evidence, not a recommendation.
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. Ask a doctor or pharmacist before use, especially with medicines, in pregnancy or for a child.
How strong the evidence is
Where blood sugar and weight sits on the supplement body map; colored by its strongest grade here.
Findings by ingredient
| Ingredient | Grade | What was studied and found |
|---|---|---|
| Beta-glucan (oat and barley) | A | Blood glucose and insulin after meals. A 2021 meta-analysis of 103 acute crossover trial comparisons (538 participants) found adding oat beta-glucan to carbohydrate meals reduced glucose response (iAUC) by 23% and insulin by 22%; certainty was high and effects depended on dose and molecular weight. sources |
| Whey protein | A | Blood glucose after a meal (whey taken before the meal). A 2023 meta-analysis of 16 randomized crossover trials (244 individuals) found whey premeals lowered peak glucose by 1.4 mmol/L versus control (high certainty); long-term effects await future trials. sources |
| Alpha-lipoic acid | B | Body weight in adults. A 2018 meta-analysis of 12 placebo-controlled trials found slightly lower body weight (−0.69 kg) and BMI (−0.38 kg/m²) with ALA, but no significant change in waist circumference. sources |
| Amla | B | Fasting blood glucose in adults. A 2023 meta-analysis of five RCTs (3-12 weeks) found lower fasting blood glucose and improved lipids with amla; authors called for more studies. sources |
| Berberine | B | Blood glucose in type 2 diabetes. NCCIH reports some evidence of a modest blood glucose-lowering effect in people with type 2 diabetes. sources |
| Beta-glucan (oat and barley) | B | Fasting glucose and HbA1c in type 2 diabetes. A 2016 meta-analysis of 4 articles (350 patients; 2.5–3.5 g/day for 3–8 weeks) found oat beta-glucan lowered fasting glucose by 0.52 mmol/L and HbA1c by 0.21%; fasting insulin did not fall significantly. sources |
| Bitter melon | B | Blood sugar control in type 2 diabetes (2019 meta-analysis). A 2019 meta-analysis of 10 studies (1,045 patients, 4–16 weeks) found single-herb preparations lowered fasting glucose (-0.72 mmol/L) and HbA1c (-0.26%) versus placebo; evidence was rated low to very low quality. sources |
| Bitter melon | B | Glucose and insulin resistance in prediabetes and type 2 diabetes (2025 meta-analysis). A 2025 meta-analysis of 25 RCTs (34 sub-studies) reported lower fasting glucose (SMD -0.46), HbA1c (SMD -0.57), insulin and HOMA-IR, with no effect on HOMA-beta. sources |
| Black seed | B | Fasting glucose and HbA1c in adults. A 2024 meta-analysis of 30 randomized trials found lower fasting glucose and HbA1c but no change in insulin or HOMA-IR; heterogeneity was very high (I² over 90%). sources |
| Carnosine (L-carnosine) | B | Blood glucose and lipids. A 2020 meta-analysis of 4 RCTs (184 participants) found lower HbA1c (-0.92%) with carnosine but no significant change in fasting blood sugar, HOMA-IR, cholesterol, triglycerides or HDL-C. sources |
| Chromium | B | Body weight and body fat. A 2019 meta-analysis (21 trials, 1,316 people, 200–1,000 mcg/day, 9–24 weeks) found about 0.75 kg more weight loss than placebo; ODS says these effects have little clinical significance. sources |
| Conjugated linoleic acid (CLA) | B | Body weight and body fat in adults. A 2024 meta-analysis of 70 RCTs (4,159 adults) found CLA lowered body mass by 0.35 kg and fat mass by 0.44 kg versus control; in high-quality trials, fat mass and body fat percentage did not change. sources |
| Conjugated linoleic acid (CLA) | B | Long-term weight in overweight and obesity. A 2012 meta-analysis of 7 RCTs lasting at least 6 months found 0.70 kg more weight loss and 1.33 kg more fat loss than placebo; the authors judged clinical relevance uncertain, and four trials had serious reporting flaws. sources |
| Ephedra | B | Short-term weight loss (pre-2004 research, usually combined with caffeine). Supplements with ephedrine alkaloids, usually plus caffeine, had modest short-term effects on weight; no studies assessed long-term effects, and NCCIH states the benefit did not outweigh the serious risks. sources |
| Garcinia cambogia | B | Body weight in adults (2011 meta-analysis). A 2011 systematic review included 12 RCTs and pooled nine: a small, statistically significant weight loss versus placebo (-0.88 kg, 95% CI -1.75 to -0.00); clinical relevance was uncertain. sources |
| Garcinia cambogia | B | Weight, BMI, body fat and waist (2020 meta-analysis). A 2020 meta-analysis of eight RCTs (530 subjects) found lower weight (-1.34 kg), BMI (-0.99 kg/m2), percentage fat mass (-0.42%) and waist circumference (-4.16 cm) than placebo. sources |
| Grape seed extract | B | Fasting glucose, lipids and inflammation markers. A 2020 meta-analysis of 50 trials reported lower fasting plasma glucose, total and LDL cholesterol, triglycerides and CRP, with no change in HbA1c, HDL cholesterol or body measurements; its abstract does not say all trials tested the extract alone. sources |
| Gymnema | B | Blood sugar in adults (randomized trials). A 2023 meta-analysis of six randomized trials found lower fasting blood sugar than control; the authors cite notable heterogeneity, low study quality and little diversity among participants. sources |
| Hibiscus (roselle) | B | Fasting glucose and lipids. A 2020 meta-analysis of randomized trials found fasting glucose 3.96 mg/dL and LDL 7.84 mg/dL lower than placebo, with no significant change in total cholesterol, HDL or triglycerides. sources |
| Inulin and FOS | B | Body weight in adults. The 2024 Talukdar meta-analysis found body weight fell 0.97 kg (36 RCTs, 1,672 participants; low certainty); effects were larger in trials of 6 weeks or more and in pre-obese and obese participants. sources |
| Inulin and FOS | B | BMI, fat mass and waist circumference. A 2024 meta-analysis of 32 studies of chicory inulin-type fructans versus placebo found lower BMI (−0.39 kg/m2), fat mass (−0.37 kg) and waist circumference (−1.03 cm). Two of three authors work for a fructan producer. sources |
| Kelp and seaweed | B | Body weight and blood lipids in adults with overweight or obesity. 2025 meta-analysis of 11 trials: seaweed lowered BMI (SMD −0.40) and percent body fat, mainly with brown seaweed for at least 8 weeks, and lowered total and LDL cholesterol; no effect on glucose metabolism. sources |
| L-carnitine | B | Blood glucose control in type 2 diabetes or insulin resistance. A 2023 meta-analysis of 41 trials (about 2,900 participants) found lower fasting glucose, insulin resistance and HbA1c; ODS states larger trials are needed. sources |
| L-carnitine | B | Body weight. A 2016 meta-analysis of 9 trials (911 participants) found an average 1.33 kg greater weight loss than placebo. sources |
| MCT oil (medium-chain triglycerides) | B | Body weight and body composition in healthy adults. A 2015 meta-analysis of 13 RCTs (749 adults) found MCTs in place of long-chain triglycerides lowered body weight by 0.51 kg and reduced waist circumference and body fat; commercial bias was detected. sources |
| MCT oil (medium-chain triglycerides) | B | Weight and glucose-lipid markers in overweight or obesity. A 2024 meta-analysis found greater weight reduction with MCT-enriched than long-chain-fat diets (−1.53%), mainly with pure MCTs, and lower blood triglycerides and HOMA-IR; medium-long-chain triglyceride diets did not significantly reduce weight. sources |
| Pomegranate | B | Blood glucose and insulin. A 2024 meta-analysis of 32 RCTs found small reductions in fasting glucose (-2.22 mg/dL), fasting insulin, HbA1c (-0.22%) and HOMA-IR; authors called for longer trials. sources |
| Pomegranate | B | Blood glucose, insulin and HbA1c (2025 pooled analysis). A 2025 meta-analysis of 34 RCTs (1,500 participants) found lower fasting glucose (-3.04 mg/dL), insulin and HOMA-IR, but no significant change in HbA1c; authors called for longer and larger trials. sources |
| Propolis | B | Blood sugar and lipids in adults with type 2 diabetes. A 2025 meta-analysis of 12 RCTs (731 adults; 9 placebo-controlled) reported lower fasting glucose, HbA1c, HOMA-IR, LDL cholesterol and triglycerides and higher HDL; glucose and HbA1c results were heterogeneous and 6 trials were from Iran. sources |
| Purslane | B | Fasting glucose and insulin resistance. A 2023 meta-analysis of RCTs found purslane lowered fasting blood glucose (weighted mean difference -6.37) but had no significant effect on insulin, HOMA-IR or QUICKI; the authors called for higher-quality trials. sources |
| Resistant starch | B | Fasting glucose and insulin resistance. A 2021 meta-analysis of 19 RCTs (excluding type 1 resistant starch and mixtures) found resistant starch lowered fasting glucose by 0.09 mmol/L and HOMA-IR by 0.33 versus digestible starch; other insulin measures did not change significantly. sources |
| Stinging nettle | B | Blood glucose in adults with type 2 diabetes (nettle supplementation). A 2020 meta-analysis of 8 RCTs (401 participants) found lower fasting blood sugar (-18.01 mg/dl) but no significant change in insulin, HOMA-IR or HbA1c; heterogeneity was high. sources |
| Taurine | B | Blood glucose, lipids and other cardiometabolic risk factors. A 2026 meta-analysis of 34 RCTs found oral taurine lowered fasting glucose (−5.90 mg/dL), HbA1c, triglycerides, total and LDL cholesterol, and systolic pressure (−4.38 mmHg); 1.5–3.0 g/day appeared more effective. sources |
| Tocotrienols | B | HbA1c, blood pressure and CRP in type 2 diabetes. A 2023 meta-analysis of 10 RCTs found tocotrienol-rich fraction (250-400 mg) lowered HbA1c (-0.23; n = 754) but did not lower systolic or diastolic blood pressure or hs-CRP. sources |
| White mulberry leaf | B | Fasting glucose, HbA1c and insulin in adults. A 2023 meta-analysis of 12 trials (615 participants) found mulberry leaf or leaf extract lowered fasting glucose by 0.47 mmol/L, HbA1c by 2.92 mmol/mol and fasting insulin by 0.58 μIU/mL. sources |
| White mulberry leaf | B | Blood glucose after meals. A 2017 meta-analysis of 13 RCTs of Morus alba products found lower post-meal glucose at 30, 60 and 90 minutes, but no difference in fasting glucose, HbA1c or HOMA-IR. sources |
| Akkermansia muciniphila (pasteurized) | C | Insulin sensitivity and metabolic markers in overweight or obese insulin-resistant adults. In a 3-month pilot RCT (40 enrolled, 32 completed), pasteurized A. muciniphila (10^10 bacteria/day) improved insulin sensitivity (+28.6%) and lowered insulinemia and total cholesterol versus placebo; body-weight change was not significant. sources |
| Akkermansia muciniphila (pasteurized) | C | Weight regain after diet-induced weight loss. In an RCT of 90 adults with overweight or obesity, 24 weeks of pasteurized MucT after an 8-week low-energy diet led to less weight regain than placebo (1.2 vs 3.2 kg). sources |
| Akkermansia muciniphila (pasteurized) | C | Body weight and HbA1c in overweight or obese type 2 diabetes (strain AKK-WST01). In a 12-week RCT of 58 participants, live AKK-WST01 did not differ from placebo in body weight or HbA1c overall; reductions appeared only in those with low baseline A. muciniphila. It does not apply directly to pasteurized products. sources |
| Aloe vera | C | Blood sugar in people with diabetes (oral). Small studies suggest oral aloe may lower fasting blood sugar and HbA1c in people with diabetes. sources |
| Aloe vera | C | Body weight in adults with overweight or obesity and diabetes or prediabetes. One small study found a specific oral gel product taken for 8 weeks modestly reduced body weight and fat mass. sources |
| Aronia (black chokeberry) | C | Fasting blood sugar and body weight. A 2026 meta-analysis of seven studies found no significant change in fasting blood sugar, body weight, BMI or waist circumference. sources |
| Asian ginseng | C | Cardiometabolic measures in prediabetes and diabetes. A 2022 review of 20 studies (1,295 participants) reported improved fasting glucose and other factors, but NCCIH calls blood-sugar research overall inconclusive and conflicting. sources |
| Astragalus | C | Blood glucose in type 2 diabetes (added to metformin). A 2024 review of 20 studies (953 adults) found larger falls in fasting glucose and HbA1c with astragalus plus metformin than metformin alone; most studies were low quality with bias. sources |
| Baikal skullcap | C | Glucose tolerance in type 2 diabetes (added to metformin). A randomized placebo-controlled crossover trial (3.52 g/day, 8-week periods) in patients already on metformin reported better glucose tolerance with the root; some participants had raised liver enzymes. sources |
| Berberine | C | Body weight. Evidence comes mainly from preliminary studies with few clinical trials in people; NCCIH finds not enough rigorous evidence to judge effectiveness. sources |
| Bitter melon | C | Blood sugar control in type 2 diabetes (Cochrane review). A 2012 Cochrane review of four RCTs (479 participants, up to 3 months, generally high risk of bias) found no significant difference in glycemic control versus placebo, metformin or glibenclamide and called the evidence insufficient. sources |
| Bitter melon | C | Metabolic syndrome measures (2024 meta-analysis). A 2024 meta-analysis of nine RCTs (414 patients, 4–16 weeks) found no significant effect versus placebo on fasting glucose, HbA1c, lipids, body weight or blood pressure; statistical power was low. sources |
| Bitter melon | C | Body weight and body composition. A 2024 meta-analysis of 10 trials (448 participants) found no significant change in body weight, BMI, waist circumference or percentage body fat. sources |
| Bitter orange | C | Body weight. Effect is unclear: studies were small with conflicting results, and most tested combination products, so bitter orange's own effect cannot be isolated. sources |
| Bitter orange | C | Weight-loss trials reviewed systematically. A 2011 systematic review of four weight-loss trials found the efficacy evidence contradictory and weak; all reviews called for longer, rigorous, larger trials. sources |
| Black ginger | C | Fasting blood glucose. A 2024 meta-analysis pooling animal studies and RCTs found lower fasting glucose in human studies (SMD -0.51, 95% CI -0.98 to -0.05). sources |
| Bladderwrack | C | Weight loss alongside a reduced-calorie diet (EU traditional use). EMA's herbal committee found clinical evidence insufficient; a study of a combined preparation in obese postmenopausal women had shortcomings, such as an inadequate statistical method, so firm conclusions could not be drawn. sources |
| Bladderwrack | C | Body weight and blood glucose in prediabetes (Ascophyllum plus Fucus extract). A 12-week RCT in 56 overweight or obese prediabetic adults found no effect of 500 mg/day brown-seaweed extract on body weight or blood glucose versus placebo; C-peptide and IL-6 changed slightly. sources |
| Bladderwrack | C | Insulin response to a carbohydrate meal (single dose). In a crossover RCT in 23 adults, 500 mg of an Ascophyllum nodosum and Fucus vesiculosus blend before 50 g of carbohydrate lowered the insulin response by 12.1% but did not change glucose. sources |
| Carrageenan and agar | C | Weight in obese adults with impaired glucose tolerance or type 2 diabetes (agar). RCT in 76 patients: adding agar to a conventional diet for 12 weeks gave greater weight loss (−2.8 vs −1.3 kg) and total cholesterol reduction than diet alone. sources |
| Chromium | C | Blood glucose in type 2 diabetes. A 2019 review of 58 trials found slightly lower fasting glucose and HbA1c of unclear clinical significance; a 24-week trial (137 people, 1,000 mcg/day picolinate) found no significant effect. sources |
| Chromium | C | Metabolic syndrome. Two trials (63 people, 500 mcg twice daily, 16 weeks; 70 people, 300 mcg/day, 24 weeks) showed no meaningful benefit. sources |
| Cinnamon | C | Blood sugar in type 1 or type 2 diabetes. Cochrane 2012: 10 RCTs, 577 participants, mostly cassia at a mean 2 g daily for 4 to 16 weeks; no significant HbA1c difference versus control, fasting glucose inconclusive, evidence insufficient. sources |
| Cissus | C | Body weight and body fat in overweight adults. In an 8-week placebo-controlled RCT of 67 overweight adults, 300 mg/day of a stem-and-leaf extract lowered body fat and waist and hip size; the investigators' university funded the study. sources |
| Cissus | C | Body weight and blood lipids in overweight and obese adults. In a placebo-controlled trial of 168 overweight or obese adults (153 completed), 300 mg/day of the same extract reduced weight, body fat, total and LDL cholesterol, triglycerides and fasting glucose. sources |
| Cumin | C | Blood sugar measures in adults. A 2021 meta-analysis of 8 RCTs (552 adults) found no significant effect of cumin on fasting glucose, insulin or HOMA-IR versus placebo. sources |
| Cumin | C | Blood sugar in chronic disease. A second 2021 meta-analysis of 8 controlled trials in people with chronic diseases reported lower fasting glucose and HbA1c, but no significant change in insulin. sources |
| Ecklonia cava | C | Post-meal blood glucose in prediabetes (12 weeks). In an RCT of 80 prediabetic adults, a dieckol-rich extract (1,500 mg/day for 12 weeks) lowered postprandial glucose versus placebo; insulin and C-peptide did not differ significantly from placebo. sources |
| Ecklonia cava | C | Post-meal blood glucose in prediabetes (single dose). In an RCT in 20 prediabetic adults, a single 600 mg dose lowered glucose at 90 and 120 minutes after a 75 g carbohydrate load, but glucose area under the curve and insulin did not differ. sources |
| Ecklonia cava | C | Glucose and lipids across marine algal polyphenol trials. A 2018 systematic review of five trials (271 adults) found small-to-medium effects on fasting glucose, total and LDL cholesterol, but inadequate evidence to confirm consistent effects. sources |
| Fenugreek | C | Blood sugar in type 2 diabetes. Some research suggests fenugreek may lower blood sugar, but many studies were not high quality; NCCIH finds not enough high-quality evidence to judge. sources |
| Flaxseed and flaxseed oil | C | Body weight in adults with overweight or obesity. One clinical trial suggests flaxseed mucilage powder mixed with water might support weight loss; flaxseed lignan extract and flaxseed oil supplements do not seem to help. sources |
| Flaxseed and flaxseed oil | C | Fasting glucose and insulin resistance in gestational diabetes. Some research suggests ALA-containing flaxseed oil supplements might improve fasting measures and insulin resistance in pregnant people with gestational diabetes. sources |
| Flaxseed and flaxseed oil | C | Blood sugar control in type 2 diabetes (lignan extract). NCCIH states more research is needed on whether flaxseed lignan extract improves glycemic control or fasting blood glucose. sources |
| Fucoidan | C | Blood sugar in type 2 diabetes. Crossover RCT in 30 patients: 1,620 mg/day for 12 weeks increased stool frequency; HbA1c fell slightly (6.73% to 6.59%) only in a subgroup of 14 without insulin resistance. sources |
| Galactooligosaccharides (GOS) | C | Insulin sensitivity in prediabetes. In a 12-week double-blind RCT in 44 overweight or obese prediabetic adults, 15 g/day GOS did not improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp, although it increased Bifidobacterium. sources |
| Garcinia cambogia | C | Body weight in adults with obesity (12-week trial). In a 12-week placebo-controlled trial cited by LiverTox, 135 adults with obesity given HCA 1,500 mg daily lost a similar amount of weight as those on placebo (3.2 vs 4.1 kg). sources |
| Garcinia cambogia | C | Weight loss overall (NCCIH assessment). NCCIH states it is unclear whether Garcinia cambogia products help with weight loss: some evidence suggests a modest effect, while other evidence shows none. sources |
| Garcinia cambogia | C | Fasting glucose, insulin and liver enzymes. A 2025 meta-analysis of nine publications (444 participants) found no significant effect on fasting blood sugar, insulin, ALT or AST compared with control groups. sources |
| Garlic | C | Blood sugar in people with diabetes. NCCIH states garlic supplements may reduce blood sugar to a small extent. sources |
| Glucomannan | C | Body weight in overweight or obese people. Pooling 8 placebo-controlled RCTs showed no statistically significant weight loss (mean difference -0.22 kg); reporting quality varied across trials. sources |
| Glucomannan | C | Weight loss (NIH ODS summary). ODS describes effects on weight as inconsistent: a 2015 review of 6 trials (293 participants, 1.24–3.99 g/day for up to 12 weeks) found no significant effect on body weight. sources |
| Glutathione | C | Insulin sensitivity in obese men with or without type 2 diabetes. A 3-week double-blind RCT in 20 men found whole-body insulin sensitivity increased with 1,000 mg/day glutathione; markers of oxidative stress did not change. sources |
| Goji | C | Blood glucose in type 2 diabetes. MSK describes preliminary data suggesting hypoglycemic effects in type 2 diabetes and states that human studies are limited. sources |
| Green tea | C | Body weight. NCCIH reports that catechins and caffeine may have a modest effect, and that results may vary with product composition and physical activity. sources |
| Gymnema | C | Glycemic control in type 2 diabetes. A 2021 meta-analysis (10 studies, 419 participants) reported reductions in fasting and post-meal glucose and HbA1c, but compared post-treatment values with baseline rather than with a control group; heterogeneity was high. sources |
| Gymnema | C | Overall effectiveness in diabetes. LiverTox states that several human trials showed mild decreases in fasting glucose, but overall effectiveness in diabetes has not been shown. sources |
| Hesperidin | C | Blood glucose control. A 2020 meta-analysis of 6 trials (318 participants) found no significant effect on fasting glucose, insulin, HbA1c, HOMA-IR or QUICKI. sources |
| Holy basil | C | Blood glucose in type 2 diabetes. A single-blind, placebo-controlled crossover trial (1996) reported fasting glucose 21.0 mg/dl and post-meal glucose 15.8 mg/dl lower with holy basil leaves than placebo leaves. sources |
| Jujube | C | Blood glucose and lipids in type 2 diabetes. In a 12-week trial in 48 adults with type 2 diabetes, 30 g/day dried jujube lowered fasting glucose, triglycerides, total and LDL cholesterol compared with control. sources |
| Kelp and seaweed | C | Glucose and lipid measures with algae and seaweed extracts. 2020 meta-analysis of 27 RCTs (1,221 participants) pooling various algae and extracts: HbA1c −0.18% and triglycerides lower, but HDL also fell and fasting glucose did not change. sources |
| Magnesium | C | Glycemic control in type 2 diabetes. Small trials conflict: magnesium oxide or chloride improved glucose measures in some, while a 3-month trial (50 insulin-treated patients, 369 mg/day) found no effect. The ADA found not enough evidence to recommend it. sources |
| Manganese | C | Type 2 diabetes. Observational studies link both higher and lower blood manganese to diabetes, and some find no association; clinical trials in humans are lacking. sources |
| Mangosteen | C | Insulin resistance in women with obesity. A 26-week randomized pilot (22 women, 20 completed) comparing behavioral therapy with or without mangosteen extract reported a significant improvement in insulin sensitivity in the mangosteen group. sources |
| Milk thistle | C | Blood sugar in type 2 diabetes. A small number of studies, mostly from Middle Eastern countries, suggest extracts may help control blood sugar; generalizability is unclear. sources |
| Moringa | C | Blood sugar, blood lipids and body weight in adults. A 2025 meta-analysis of nine randomized trials (649 participants) found no significant effect on most cardiometabolic outcomes; GRADE certainty was very low for all outcomes. sources |
| Myo-inositol | C | Metabolic and hormonal measures in PCOS. A guideline meta-analysis of 30 trials (2,230 women) found possible benefits for some metabolic measures but likely no effect on other outcomes; evidence was limited and inconclusive. sources |
| Neem | C | Blood sugar in adults with metabolic syndrome. One 12-week RCT (80 adults; 125-500 mg twice daily of a leaf-and-twig extract) reported dose-dependent improvements in fasting glucose, HbA1c and insulin resistance. sources |
| NMN (nicotinamide mononucleotide) | C | Body weight, glucose and blood lipids in adults. A meta-analysis of 15 randomized trials found no significant effects on body weight, BMI, fasting glucose, HbA1c or lipids; insulin resistance (HOMA-IR) showed a non-significant downward trend. sources |
| Olive leaf extract | C | Fasting blood glucose and cardiometabolic markers. A meta-analysis of 12 RCTs (703 adults, 2 days to 12 weeks) found that fasting glucose, in studies using low doses, favored the control group; authors called for more consistent trials. sources |
| Potassium | C | Blood glucose. Observational studies link low intake with higher diabetes risk; one small trial (29 adults with prediabetes, 40 mEq/day for 3 months) lowered fasting glucose only. sources |
| Prickly pear | C | Body weight in adults. A 2015 meta-analysis of five RCTs found no significant difference in body weight between Opuntia ficus-indica and controls (mean difference -0.83 kg, 95% CI -2.49 to 0.83); trials varied in design and reporting quality. sources |
| Prickly pear | C | Blood glucose and insulin, fruit versus cladode. A 2019 systematic review of 20 human studies found cladode and some Opuntia products mostly reduced glucose and insulin, while the fruit mostly had no significant effect; fruit and cladode studies had high risk of bias. sources |
| Purslane | C | Type 2 diabetes on one oral glucose-lowering drug. A 12-week placebo-controlled RCT (63 adults) of purslane extract found a larger systolic blood pressure drop (-7.5 vs -0.01 mmHg); HbA1c fell more only in a subgroup of responders. sources |
| Reishi | C | Blood sugar, lipids and blood pressure in type 2 diabetes. Cochrane 2015: 5 trials (398 participants). In pooled data from type 2 diabetes trials (1.4–3 g/day, 12–16 weeks), HbA1c, cholesterol, blood pressure and triglycerides did not differ from placebo; risk of bias was unclear in 4 of 5 trials. sources |
| Resistant starch | C | Type 2 diabetes risk. FDA concluded there is limited credible evidence for a relationship between high-amylose maize starch (at least 50% RS2) and reduced type 2 diabetes risk; a few studies with mixed surrogate-endpoint results suggested a reduction. sources |
| Resveratrol | C | Blood sugar control in type 2 diabetes. A Cochrane review of 3 trials (50 adults; 10–1,000 mg/day for 4–5 weeks) found neutral effects on HbA1c, fasting glucose and insulin resistance; evidence was insufficient to judge efficacy or safety. sources |
| Royal jelly | C | Blood sugar markers. A 2019 meta-analysis of 5 placebo-controlled trials found no significant effect on fasting glucose (205 participants) or HbA1c (130 participants); the authors cite methodology issues and confounders such as diet. sources |
| Safflower | C | Seed oil: blood sugar in obese postmenopausal women with type 2 diabetes. In one double-masked crossover RCT (55 enrolled, 35 completed), 8 g/day safflower oil for 16 weeks lowered HbA1c and raised HDL cholesterol. sources |
| Sage | C | Blood sugar. NCCIH: there is not enough evidence to show whether sage affects blood glucose. sources |
| Sage | C | Blood sugar and lipids in diabetes. A meta-analysis of 3 trials in people with diabetes reported lower fasting glucose (−31.15 mg/dL) and HbA1c (−0.94%); the authors called for stronger trials because so few exist. sources |
| Schisandra | C | Blood glucose in adults with mild hyperglycemia (omija and soybean mixture). A 12-week placebo-controlled trial in 80 adults found lower fasting and post-meal glucose with an omija-soybean extract mixture; schisandra alone was not tested. sources |
| Sea buckthorn | C | Blood glucose, blood pressure and BMI. The 2022 Geng meta-analysis of 15 RCTs found no effect on blood sugar, blood pressure or body mass index. sources |
| Spirulina | C | Body weight and body fat in adults. A 2025 meta-analysis of 17 RCTs found small reductions in body weight (-1.07 kg), BMI (-0.40) and body fat percentage (-0.84%), but no significant change in waist circumference. sources |
| Stevia | C | Blood sugar and HbA1c. The 2019 Bundgaard Anker meta-analysis found no significant effect on HbA1c and only a non-significant reduction in fasting blood glucose. sources |
| Sumac | C | Insulin, glucose and body weight. In the 2025 Huang meta-analysis of 17 trials, insulin (−1.68 µU/mL), HOMA-IR and body weight (−1.03 kg) fell versus control, but fasting blood glucose did not change significantly. sources |
| Sumac | C | Glycemic measures (earlier pooled analysis). A 2021 meta-analysis of 6 trials (278 participants) found no significant effect of sumac powder on fasting glucose, HbA1c, HOMA-IR or insulin. sources |
| Tart cherry | C | Blood sugar and lipids. A meta-analysis of 10 randomized trials found a small fall in fasting blood sugar (−0.51 mg/dl) and no effect on total cholesterol, triglycerides or HDL cholesterol. sources |
| Thiamin (vitamin B1) | C | Diabetes. Small studies used 150–300 mg/day thiamin and three benfotiamine trials used 120–900 mg/day; ODS states larger, longer, well-designed studies are required. sources |
| Ubiquinol | C | Glucose control in type 2 diabetes. A 12-week RCT (50 patients, 100 mg/day liquid ubiquinol) reported lower HbA1c than placebo (P = 0.03) and higher catalase and glutathione peroxidase activities. sources |
| Vitamin K2 (menaquinone-7) | C | Glycemic control and blood lipids. A 2025 meta-analysis of six RCTs reported lower insulin, HbA1c and HOMA-IR with MK-7, with high heterogeneity (I2 84-87%), and no meaningful effect on other measures; authors called for higher-quality trials. sources |
| White mulberry leaf | C | Overall blood sugar management (2022 review). A 2022 systematic review of RCTs found Morus alba can reduce post-meal glucose and insulin but judged the evidence insufficient to conclude it is effective for lowering blood glucose. sources |
| White mulberry leaf | C | Obese adults with borderline diabetes. In a 12-week randomized study, leaf powder (12 mg DNJ three times daily) lowered fasting glucose by 3.86 mg/dL and HbA1c by 0.11% from baseline; glucose tolerance did not improve. sources |
| Zinc | C | Type 2 diabetes and glucose measures. Meta-analyses reported improved glucose and lipid measures, but ODS concludes the evidence to date is insufficient to support any conclusions. sources |
| Buchu | D | Blood glucose, weight and blood pressure in rats. Aqueous buchu extract normalized glucose in diabetic rats, and in rats on a high-fat diet it reduced weight gain and returned diet-raised blood pressure to control values; the review authors say these results remain questionable in humans without trials. sources |
| Chaga | D | Blood sugar. Terpenoids inhibited the enzyme alpha-glucosidase in laboratory tests, and antidiabetic effects were studied in diabetic mice; not studied in people. sources |
| Rooibos | D | Blood glucose in diabetic rodents. A meta-analysis of 12 rodent studies found lower blood glucose with rooibos extracts or their polyphenols, with substantial heterogeneity; no human data were included. sources |
| Akkermansia muciniphila (pasteurized) | X | Whole-body insulin sensitivity in adults with metabolic syndrome. In a double-blind placebo-controlled trial of 142 adults, 4 months of pasteurized MucT (30 billion cells/day) did not change the primary endpoint (Matsuda index); benefits appeared only in exploratory subgroups. sources |
| Betaine (trimethylglycine) | X | Body weight and body composition. A 2022 meta-analysis found betaine did not significantly change body mass, BMI, body fat percentage, fat mass or fat-free mass compared with control. sources |
| Calcium | X | Body weight and body fat. A meta-analysis of 41 RCTs (4,802 adults) found calcium supplements had no effect on weight or body fat. sources |
| Nicotinamide riboside | X | Insulin sensitivity in obese, insulin-resistant men. A 12-week randomized trial in 40 men (2,000 mg/day) found no improvement in clamp-measured insulin sensitivity, glucose metabolism, energy expenditure or body composition. sources |
| Vitamin D | X | Type 2 diabetes in prediabetes. A trial in 2,423 adults with prediabetes and overweight or obesity (4,000 IU/day D3, median 2.5 years) found no significant reduction in diabetes versus placebo. sources |
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.